Clinico-demographic profile & hospital outcomes of COVID-19 patients admitted at a tertiary care centre in north India.
COVID-19
Clinico-epidemiologic
cough
north India
outcome
prospective
Journal
The Indian journal of medical research
ISSN: 0971-5916
Titre abrégé: Indian J Med Res
Pays: India
ID NLM: 0374701
Informations de publication
Date de publication:
Historique:
pubmed:
11
8
2020
medline:
30
9
2020
entrez:
11
8
2020
Statut:
ppublish
Résumé
In December 2019, a novel coronavirus (SARS-CoV-2) emerged in China and rapidly spread globally including India. The characteristic clinical observations and outcomes of this disease (COVID-19) have been reported from different countries. The present study was aimed to describe the clinico-demographic characteristics and in-hospital outcomes of a group of COVID-19 patients in north India. This was a prospective, single-centre collection of data regarding epidemiological, demographic, clinical and laboratory parameters, management and outcome of COVID-19 patients admitted in a tertiary care facility in north India. Patient outcomes were recorded as death, discharge and still admitted. Data of 144 patients with COVID-19 were recorded and analyzed. The mean age of the patients was 40.1±13.1 yr, with 93.1 per cent males, and included 10 (6.9%) foreign nationals. Domestic travel to or from affected States (77.1%) and close contact with COVID-19 patients in congregations (82.6%) constituted the most commonly documented exposure. Nine (6.3%) patients were smokers, with a median smoking index of 200. Comorbidities were present in 23 (15.9%) patients, of which diabetes mellitus (n=16; 11.1%) was the most common. A significant proportion of patients had no symptoms (n=64; 44.4%); among the symptomatic, cough (34.7%) was the most common symptom followed by fever (17.4%) and nasal symptoms (2.15%). Majority of the patients were managed with supportive treatment with hydroxychloroquine and azithromycin given on a case-to-case basis. Only five (3.5%) patients required oxygen supplementation, four (2.8%) patients had severe disease requiring intensive care, one required mechanical ventilation and mortality occurred in two (1.4%) patients. The time to reverse transcription-polymerase chain reaction (RT-PCR) negativity was 16-18 days. In this single-centre study of 144 hospitalized patients with confirmed COVID-19 in north India, the characteristic findings included younger age, high proportion of asymptomatic patients, long time to PCR negativity and low need for intensive care unit care.
Sections du résumé
BACKGROUND & OBJECTIVES
OBJECTIVE
In December 2019, a novel coronavirus (SARS-CoV-2) emerged in China and rapidly spread globally including India. The characteristic clinical observations and outcomes of this disease (COVID-19) have been reported from different countries. The present study was aimed to describe the clinico-demographic characteristics and in-hospital outcomes of a group of COVID-19 patients in north India.
METHODS
METHODS
This was a prospective, single-centre collection of data regarding epidemiological, demographic, clinical and laboratory parameters, management and outcome of COVID-19 patients admitted in a tertiary care facility in north India. Patient outcomes were recorded as death, discharge and still admitted.
RESULTS
RESULTS
Data of 144 patients with COVID-19 were recorded and analyzed. The mean age of the patients was 40.1±13.1 yr, with 93.1 per cent males, and included 10 (6.9%) foreign nationals. Domestic travel to or from affected States (77.1%) and close contact with COVID-19 patients in congregations (82.6%) constituted the most commonly documented exposure. Nine (6.3%) patients were smokers, with a median smoking index of 200. Comorbidities were present in 23 (15.9%) patients, of which diabetes mellitus (n=16; 11.1%) was the most common. A significant proportion of patients had no symptoms (n=64; 44.4%); among the symptomatic, cough (34.7%) was the most common symptom followed by fever (17.4%) and nasal symptoms (2.15%). Majority of the patients were managed with supportive treatment with hydroxychloroquine and azithromycin given on a case-to-case basis. Only five (3.5%) patients required oxygen supplementation, four (2.8%) patients had severe disease requiring intensive care, one required mechanical ventilation and mortality occurred in two (1.4%) patients. The time to reverse transcription-polymerase chain reaction (RT-PCR) negativity was 16-18 days.
INTERPRETATION & CONCLUSIONS
CONCLUSIONS
In this single-centre study of 144 hospitalized patients with confirmed COVID-19 in north India, the characteristic findings included younger age, high proportion of asymptomatic patients, long time to PCR negativity and low need for intensive care unit care.
Identifiants
pubmed: 32773414
pii: 290525
doi: 10.4103/ijmr.IJMR_1788_20
pmc: PMC7853260
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
61-69Déclaration de conflit d'intérêts
None
Références
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Clin Microbiol Infect. 2020 Aug;26(8):1063-1068
pubmed: 32251842
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Indian J Med Res. 2020 May;151(5):424-437
pubmed: 32611914
Med Mal Infect. 2020 Jun;50(4):384
pubmed: 32240719
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
Monaldi Arch Chest Dis. 2020 Apr 10;90(1):
pubmed: 32290644
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Tob Induc Dis. 2020 Mar 20;18:20
pubmed: 32206052
Osong Public Health Res Perspect. 2020 Apr;11(2):85-90
pubmed: 32257774
Nicotine Tob Res. 2020 Aug 24;22(9):1653-1656
pubmed: 32399563
J Med Virol. 2020 Oct;92(10):1733-1734
pubmed: 32242950
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219
pubmed: 32391667
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Mediators Inflamm. 2012;2012:649570
pubmed: 22719178
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Indian J Med Res. 2020 May;151(5):490-492
pubmed: 32611918